Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200741 | 0.87 | ACE (0.56) | ACEMMECASP1 | |
| SCHEMBL10263278 | 0.83 | ACE (0.40) | ACEMMECASP1 | |
| SCHEMBL12946454 | 0.81 | CASP1 (0.55) | ACEMMECASP1 | |
| SCHEMBL12450752 | 0.81 | CASP1 (0.55) | ACEMMECASP1 | |
| SCHEMBL10200742 | 0.81 | CASP1 (0.65) | ACEMMECASP1 | |
| SCHEMBL10200744 | 0.81 | ACE (0.44) | ACEMMECASP1 | |
| SCHEMBL12443691 | 0.78 | LCK (0.43) | ACEMMECASP1 | |
| SCHEMBL645030 | 0.77 | ACE (0.68) | ACEMMECASP1 | |
| SCHEMBL645727 | 0.77 | ACE (0.68) | ACEMMECASP1 | |
| SCHEMBL12443714 | 0.76 | MME (0.48) | ACEMMETPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ACE 6/4885MME 97/4885CASP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.